Akums Drugs and Pharmaceuticals Limited
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.
What Akums files
- Others54
- Investor Meet45
- Important34
- Updates15
- Board Meeting12
- PPTs6
Here's a concise summary of Akums' investor presentation: **1. Business Performance:** Akums delivered a strong FY26 performance, especially in H2, driven by robust volume growth in its CDMO business despite muted domestic market volumes. Gross margins improved significantly due to strong cost-optimization. CDMO contributed 80% to full-year revenue. **2. Growth...
**1. Business Performance:** The financial results for the quarter and half-year show H1FY26 revenue largely flat, but margins dipped due to an 8-10% YoY fall in API prices. CDMO volumes grew 7%. Q2FY26 revenue was ₹1,018 Cr (-1.5% YoY) with Adjusted PAT at ₹43 Cr (-35.9% YoY) and Adjusted EBITDA...
Here is the financial summary: **Financial Highlights:** * Q1 FY26 consolidated total income reached ₹1,051 Cr (+2.4% YoY). Adjusted EBITDA stood at ₹156 Cr (14.8% margin, +208 bps YoY), with Adjusted PAT at ₹65 Cr (6.2% margin, +57 bps YoY). * Cash surplus surged to ₹1,518 Cr (from ₹566 Cr...
1. Financial Highlights: Akums reported flat consolidated revenue of ₹4,170 Cr for FY25 (-1%), with adjusted EBITDA margin expanding to 12.3% (+7bps) and adjusted PAT margin rising to 5.6% (+38bps). Q4 revenue rose 12.4% to ₹1,073 Cr while PAT margin slightly dipped to 4.1%. The CDMO segment saw stable EBITDA...
1. **Financial Highlights**: For Q3 FY25, Akums Drugs and Pharmaceuticals reported a total income of ₹10,250 Cr, slightly down from ₹10,918 Cr in Q3 FY24. Adjusted EBITDA rose to ₹1,359 Cr with a margin of 13.3%, up from 11.1% a year earlier. Adjusted PAT increased to ₹663 Cr, marking a...